reports
- Sid Rajeev
A Potential Breakthrough in Spinal Cord and Optic Nerve Injury Treatme...
**NurExone Biologic Inc. (TSXV: NRX / OTCQB: NRXBF / FSE: J90): Initiating Coverage** NurExone Biologic Inc., an Israeli biotech, is advancing regenerative medicine using exosomes for targeted therapies in spinal cord and optic nerve injuries. Its lead product, **ExoPTEN**, has shown preclinical promise, securing orphan drug designation from the FDA and EMA, with clinical trials expected by late 2025. Operating in the emerging exosome therapeutics space, NurExone is well-positioned for growth ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.